Belzutifan outperforms everolimus in advanced kidney cancer treatment
Belzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer, in patients previously treated with immune checkpoint inhibitors and anti-angiogenic ...
Oct 22, 2023
0
1